Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
The convergence of two trends makes Chris Claxton, the vice president of investor relations at UK-based Horizon Discovery, believe that his company is in the right place at the right time. 20 November 2017
Alnylam Pharmaceuticals, which with some justification bills itself as the leading RNAi company, isn’t shy of mentioning the Nobel-prize winning provenance of its science and technology. 17 November 2017
Taipei-based generics maker TWi Pharmaceuticals has bought Synpac-Kingdom Pharmaceutical (SKP), another generics supplier known for ophthalmic treatments, for NT$1.8 billion ($59.8 million), reports The Pharma Letter’s China correspondent Wang Fangqing. 17 November 2017
Canadian clinical-stage immuno-oncology (I-O) company Turnstone Biologics has named Mike Burgess as president of research and development (R&D). 16 November 2017
In an area like oncology, innovation is needed not just with the end product, but in the way that researchers get there, finds Rik Van Mol, vice president of R&D strategy at software provider Veeva Systems, in an Expert View piece looking at a leading cancer charity’s modernization of clinical operations. 15 November 2017
US pharma giant Pfizer has promoted Albert Bourla to the newly-created position of chief operating officer, effective January 1, 2018. 15 November 2017
UK-based Pertinax Pharma says that Nigel Brooksby, a former chairman of Sanofi UK, has been appointed as chairman of the company, where he will drive the commercialization of the company’s Pertinax. 14 November 2017
Thomas Busby and Oded Ben-Joseph, from investment bank Outcome Capital, look at some of the hurdles to accessing venture capital, and how companies can overcome them. 10 November 2017
In an Expert View piece, Ulrike Gottwald-Hostalek, senior medical director at Merck KGaA, and Kerstin Brand, director of global medical affairs for diabetes at the German pharma major, consider the case of a therapy that has stood the test of time. 10 November 2017
Boosted by his firm’s positive Phase III presentation at last week’s ATTR meeting, Alnylam Pharmaceuticals’ EVP of research and development Akshay Vaishnaw won’t commit to saying that regulatory approval is inevitable, but he and president Barry Greene certainly give that impression. 10 November 2017
This year my intensive use of the Japanese health care system continued apace with four operations, multiple doctor appointments, and enumerable test procedures, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter. 9 November 2017
Belgian biotech firm ThromboGenics, which is focussed on developing novel medicines for back of the eye diseases and focused on diabetic eye disease, today announced it has strengthened its senior leadership team, attracting former executives from Allergan and Novartis. 8 November 2017
In light of the progress and potential of cell and gene therapies, Amy Grogg, senior vice president of strategy and communication at US drug wholesale company AmerisourceBergen, considers the strategies needed to overcome challenges around market access and the complexity of commercialization in an expert view column. 7 November 2017
Chirfi Guindo has been appointed executive vice president and head of global marketing, market access and customer innovation at US biotech major Biogen. 3 November 2017
Swiss drugmaker Basilea Pharmaceutica has reported that Achim Kaufhold will retire from his post as chief medical officer after seven years with the company. 1 November 2017
An expert view piece by Steven Shill, Patrick Pilch and David Friend from the BDO Center for Healthcare Excellence & Innovation, on what drug manufacturers should watch in the wake of natural disasters. 31 October 2017
French pharma major Sanofi plans to increase the volume of insulin production at its Russian plant operated by CJSC Sanofi-Aventis Vostok more than four-fold. 31 October 2017